HLA-A Antigens (HLA-A)

Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.

Also Known As:

Networked: 1737 relevant articles (27 outcomes, 197 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sugiyama, Haruo: 14 articles (02/2014 - 08/2002)
2.	Oka, Yoshihiro: 12 articles (02/2014 - 12/2002)
3.	Tsuboi, Akihiro: 11 articles (02/2014 - 12/2002)
4.	Oji, Yusuke: 10 articles (02/2014 - 12/2002)
5.	Kuzushima, Kiyotaka: 10 articles (09/2013 - 09/2004)
6.	Morishima, Yasuo: 9 articles (02/2015 - 06/2002)
7.	Nakamura, Yusuke: 9 articles (08/2014 - 12/2004)
8.	Barton, James C: 9 articles (01/2014 - 10/2002)
9.	Tokunaga, Katsushi: 9 articles (01/2014 - 01/2002)
10.	Takiguchi, Masafumi: 8 articles (07/2015 - 01/2002)

Related Diseases

1.	Infection 08/01/2008 - "We demonstrated no statistical significant dependences between HCV infection course and efficacy of its treatment children and youth HLA A antigens. " 04/01/2002 - "In conclusion, this retrospective analysis shows that more HLA-A, -B compatibilities seems to be associated with an improved graft survival in patients after OLT for end-stage HBV infection." 10/01/2011 - "HLA-A, -B, -C, -DRB1 and -DQB1 genotyping were performed in 135 HCV-infected Brazilian patients among which 45 cleared HCV infection (cases) and 90 had persistent viral infection (controls). " 01/01/2009 - "HLA-A, -C, -DRB1 and -DQB1 genotyping were performed in a Midwestern American cohort of 105 HCV infected subjects among which 49 cleared HCV infection and 56 had persistent viral infection. " 08/01/2008 - "It is possible that course if HCV infection and efficacy of antiviral treatment are depended on HLA A antigens."
2.	Leukemia 04/01/2014 - "The purpose of this study was to evaluate the potential associations between HLA-A, B, DRB1 gene and leukemia. " 03/01/2015 - "From a leukemia cell line, we identified a CDK4-derived peptide epitope, UNC-CDK4-1 (ALTPVVVTL), that bound HLA-A*02:01 with high affinity and could induce CD8⁺ T-cell responses in vitro. " 08/01/2014 - "We previously reported ESK1, a high avidity (Kd < 0.2 nmol/L), fully-human monoclonal antibody (mAb) specific for the WT1 RMF peptide/HLA-A*02:01 complex, which selectively bound and killed WT1(+) and HLA-A*02:01(+) leukemia and solid tumor cell lines. " 06/01/2013 - "A novel HLA-A allele, A*66:17 was revealed in a family of a leukemia patient during high-resolution HLA typing." 04/01/2013 - "[Correlation of HLA-A, B, DRB1 genes with leukemia]."
3.	Neoplasms (Cancer) 01/01/2012 - "To provide further evidence for the NPC susceptibility in the region near HLA-A locus based on other previous studies, we carried out a two-stage hospital-based case control association study including 535 sporadic NPC patients and 525 cancer-free control subjects from Guangdong, a high prevalence area of NPC in China. " 01/01/2012 - "Previous studies mainly focused on the expression of HLA-A in tumor cells. " 11/15/2005 - "The results of the present study indicate that HLA-A polymorphism is one of the host genetic factors that alter the risk for the development of cervical cancer in Chinese women." 10/01/2005 - "We investigated the frequency and relationship between HLA-A-B and HLA-A-B-DR haplotypes among women with cervical cancer/high-grade lesions (n=365) and cytologically normal population controls (n=681) within three cervical neoplasia studies in the US and Costa Rica. " 03/01/1991 - "In the current study, we have investigated T cell lines from patients who are heterozygous at HLA-A region locus, to determine the relative importance of each A-region allele in this MHC-restricted recognition of tumor. "
4.	Melanoma (Melanoma, Malignant) 01/01/2013 - "We enrolled 33 stage III and IV HLA-A*02:01-positive patients with melanoma in this study, of whom 29 were evaluable for immunologic response. " 09/01/1996 - "This study was done to identify HLA-A*02 subtypes and their prevalence in two ancestrally different white melanoma populations. " 12/18/2015 - "Therefore, we analyzed by in vitro experiments the effect on antigen processing and recognition of a T210M exchange, which previously had been introduced into the melanoma gp100209-217tumor epitope to improve the HLA-A*02:01 binding and its immunogenicity. " 05/15/2015 - "The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. " 01/15/2014 - "This revealed that of the four HLA-A*02:06-restricted melanoma-associated T cell responses observed in this patient, two responses were underestimated and one was overlooked when using subtype-mismatched pMHC multimer collections. "
5.	Graft vs Host Disease (Graft-Versus-Host Disease) 01/01/2014 - "Polymorphisms of HLA genes represent a major barrier to HSCT because HLA-A, -B, -C and DRB1 incompatibilities confer a higher risk of acute graft-versus-host disease (aGVHD) and mortality. " 06/10/2010 - "The risk of acute graft-versus-host disease (GVHD) of these HLA haplotypes was assessed with multivariate Cox regression in 712 patients transplanted from HLA fully (HLA-A, B, C, DRB1, DQB1, and DPB1) matched unrelated donors. " 10/01/2004 - "We therefore examined the effects of HLA matching (low or high resolution or both) on engraftment, graft-versus-host disease (GVHD), and mortality in 1874 donor-recipient pairs retrospectively typed at high resolution for HLA-A, -B, -C, -DRB1, -DQ, and -DP. " 04/01/1995 - "Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings." 02/01/1989 - "Implication of a gene distal to HLA-A in the etiology of graft-versus-host disease."

Related Drugs and Biologics

1.	Antigens
2.	HLA-DRB1 antigen (HLA DRB1)
3.	HLA-B Antigens (HLA-B)
4.	HLA-C Antigens (HLA-C)
5.	Monoclonal Antibodies
6.	HLA-DQB1 antigen (HLA DQB1)
7.	HLA-A Antigens (HLA-A)
8.	Muromonab-CD3 (Muromonab CD3)
9.	HLA-D Antigens
10.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Transplantation (Transplant Recipients)
3.	Drug Therapy (Chemotherapy)
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
5.	Homologous Transplantation (Allograft)